Yicura BioMed completes first closing of Series B financing

详细摘要
Clinical-stage immunotherapy firm Yicura BioMed completed the first closing of its Series B funding round led by Gobi Partners on 13 November 2026 to advance its ICVAX HIV product.
HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases, is pleased to announce today the first closing of its Series B financing led by Gobi Partners, with participation from a number of strategic investors from Wuxi and institutional investors from Hong Kong. Their participation reflects shared confidence in Yicura's clinical development path.
The issuer is solely responsible for the content of this announcement.
文章开头,摘自Vietnam Investment Review。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (vir.com.vn)




